Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameUmp
Stock Code00722
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities本集團是香港前列的企業醫療保健解決方案提供者,透過UMP醫務中心及聯屬診所組成的網絡,向合約客戶及自費患者提供全面的醫療保健服務,包括醫療服務、牙科服務及輔助服務。
Listing Date2015-11-27
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)香港德輔道中71號永安集團大廈27樓
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.ump.com.hk
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 2.06 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2015-11-17 to 2015-11-20
Global Offering Shares184,000,000 shares
HK Public Offer Shares (Initial)18,400,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)165,600,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO736,000,000 shares
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 379,040,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 341M
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +2654%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)900.0百万港元
P/E RatioNot disclosed
Profit/Loss Status盈利约40.9百万港元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO Investment约370.4百万港元

Financial Data

Unit: RMB
Income Statement
Item 2013-062014-062015-06
Revenue 4,642,35616,760,65624,411,458
Cost of sales -138,617-279,498
Other income and gains, net 56,26960,86561,749
Profit before tax -152,7734,504,9525,409,586
Income tax expense -75,347-393,681-1,312,246
Profit for the year -228,1204,111,2714,097,340
Balance Sheet
Item 2013-062014-062015-06
Cash and cash equivalents 2,171,8856,696,13110,274,553
Trade and bills receivables 366,803264,830173,749
Inventories 1,616113,828120,671
Total current assets 7,183,00712,621,89715,175,559
Total current liabilities 4,767,30310,210,2768,295,528
Total equity 5,605,7829,717,05313,814,393
Cash Flow Statement
Item 2013-062014-062015-06
Net cash from operating activities 1,701,6774,381,7785,789,205
Net cash from investing activities -2,944,114-209,283-703,219
Net cash from financing activities 1,674,533351,751-1,507,564
Net increase in cash 432,0964,524,2463,578,422
Depreciation of PP&E 228,494816,8781,057,196
Purchase of PP&E -2,950,383-1,204,818-752,276
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 1.93
First Day OpenHK$ 1.81
First Day Change-6.31%
First Day Volume67576000.0
First Day Turnover127797000.0
Use of Proceeds
1、約200.2百萬港元(約60.0%)將用于集團在中國的擴展; 2、約100.1百萬港元(約30.0%)將用于擴大本集團在香港的業務; 3、剩余所得款項約33.4百萬港元(約10.0%)將用作本集團的營運資金及其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
J.P. Morgan Securities (Far East) Limited CE AAB026
Overall Coordinators (1)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
Joint Bookrunners (2)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 CGS International Securities Hong Kong Limited CE AAW351
Joint Lead Managers (2)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 CGS International Securities Hong Kong Limited CE AAW351

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman孫耀江—
Company Secretary馬凱雲—
No director data available.

Major Shareholders

Major Shareholders & Holdings控股股東孫耀江醫生透過East Majestic及EM Team合共持有約33.12%股權;周大福企業透過Healthcare Ventures持股15%;鳳凰醫療透過Pinyu持股15%。
About this page

This page shows Ump (00722) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect